Drug acetylation in breast cancer

Br J Cancer. 1989 Aug;60(2):236-7. doi: 10.1038/bjc.1989.260.


The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation
  • Breast Neoplasms / metabolism*
  • Female
  • Humans
  • Isoniazid / metabolism*


  • Isoniazid